Bluejay Diagnostics, Inc. (BJDX)
NASDAQ: BJDX · Real-Time Price · USD
1.010
-0.020 (-1.94%)
At close: Sep 9, 2026, 4:00 PM EDT
0.9750
-0.0350 (-3.47%)
After-hours: Sep 9, 2026, 4:28 PM EDT
Bluejay Diagnostics Employees
Bluejay Diagnostics had 6 employees as of December 31, 2025. The number of employees decreased by 1 or -14.29% compared to the previous year.
Employees
6
Change (1Y)
-1
Growth (1Y)
-14.29%
Revenue / Employee
n/a
Profits / Employee
-$1,211,783
Market Cap
4.51M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 6 | -1 | -14.29% |
| Dec 31, 2024 | 7 | -3 | -30.00% |
| Dec 31, 2023 | 10 | -6 | -37.50% |
| Dec 31, 2022 | 16 | 7 | 77.78% |
| Dec 31, 2021 | 9 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Vivos Therapeutics | 270 |
| WORK Medical Technology Group LTD | 238 |
| VolitionRx | 57 |
| Beyond Air | 54 |
| Nuwellis | 38 |
| Tenon Medical | 26 |
| Catheter Precision | 17 |
| ENvue Medical | 14 |
BJDX News
- 1 day ago - Bluejay Diagnostics and Lovell Government partner to access federal healthcare - TheFly
- 1 day ago - Bluejay Diagnostics and Lovell Government Services Announce Partnership to Expand Access to U.S. Federal Healthcare Markets - GlobeNewsWire
- 27 days ago - Bluejay Diagnostics Reports Q2 2026 Results; Strengthened Balance Sheet Supports Advancement of Symphony™ IL-6 Toward Regulatory Submission and Commercialization - GlobeNewsWire
- 7 weeks ago - Bluejay Diagnostics completes enrollment in SYMON-II study - TheFly
- 7 weeks ago - Bluejay Diagnostics Announces Successful Completion of Enrollment in the SYMON-II Multicenter Clinical Validation Study - GlobeNewsWire
- 2 months ago - Bluejay Diagnostics files to sell 11.22M shares of common stock for holders - TheFly
- 3 months ago - Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules - GlobeNewsWire
- 3 months ago - Bluejay Diagnostics Announces up to $23.6 Million Private Placement Priced At-the-Market Under Nasdaq Rules - GlobeNewsWire